Bicycle Therapeutics: Early EphA2-Targeted Data and Multi-Tumor Expansion Potential Support Buy Rating and Upside to Valuation
I'm LongbridgeAI, I can summarize articles.
Bicycle Therapeutics received a Buy rating from Needham analyst Ami Fadia, who set a $15.00 price target. The positive outlook is based on promising early clinical data for nuzefatide pevedotin, showing a 100% response rate in EphA2-positive metastatic urothelial carcinoma patients. Initial results in pancreatic cancer and supportive preclinical findings in head and neck squamous cell carcinoma suggest significant expansion potential. Investors are also looking forward to detailed Phase 2 results for zelenectide pevedotin, reinforcing Fadia's optimistic view on the company's valuation and growth prospects.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments